242 related articles for article (PubMed ID: 31740444)
1. USP22 Functions as an Oncogenic Driver in Prostate Cancer by Regulating Cell Proliferation and DNA Repair.
McCann JJ; Vasilevskaya IA; Poudel Neupane N; Shafi AA; McNair C; Dylgjeri E; Mandigo AC; Schiewer MJ; Schrecengost RS; Gallagher P; Stanek TJ; McMahon SB; Berman-Booty LD; Ostrander WF; Knudsen KE
Cancer Res; 2020 Feb; 80(3):430-443. PubMed ID: 31740444
[TBL] [Abstract][Full Text] [Related]
2. Ubiquitin-specific protease 22 is critical to in vivo angiogenesis, growth and metastasis of non-small cell lung cancer.
Zhang K; Yang L; Wang J; Sun T; Guo Y; Nelson R; Tong TR; Pangeni R; Salgia R; Raz DJ
Cell Commun Signal; 2019 Dec; 17(1):167. PubMed ID: 31842906
[TBL] [Abstract][Full Text] [Related]
3. A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2).
Mazzu YZ; Armenia J; Chakraborty G; Yoshikawa Y; Coggins SA; Nandakumar S; Gerke TA; Pomerantz MM; Qiu X; Zhao H; Atiq M; Khan N; Komura K; Lee GM; Fine SW; Bell C; O'Connor E; Long HW; Freedman ML; Kim B; Kantoff PW
Clin Cancer Res; 2019 Jul; 25(14):4480-4492. PubMed ID: 30996073
[TBL] [Abstract][Full Text] [Related]
4. USP22 exerts tumor-suppressive functions in colorectal cancer by decreasing mTOR activity.
Kosinsky RL; Zerche M; Saul D; Wang X; Wohn L; Wegwitz F; Begus-Nahrmann Y; Johnsen SA
Cell Death Differ; 2020 Apr; 27(4):1328-1340. PubMed ID: 31527800
[TBL] [Abstract][Full Text] [Related]
5. USP22-dependent HSP90AB1 expression promotes resistance to HSP90 inhibition in mammary and colorectal cancer.
Kosinsky RL; Helms M; Zerche M; Wohn L; Dyas A; Prokakis E; Kazerouni ZB; Bedi U; Wegwitz F; Johnsen SA
Cell Death Dis; 2019 Dec; 10(12):911. PubMed ID: 31801945
[TBL] [Abstract][Full Text] [Related]
6. USP22 positively modulates ERα action via its deubiquitinase activity in breast cancer.
Wang S; Zhong X; Wang C; Luo H; Lin L; Sun H; Sun G; Zeng K; Zou R; Liu W; Sun N; Song H; Liu W; Zhang Q; Liao Z; Teng X; Zhou T; Sun X; Zhao Y
Cell Death Differ; 2020 Nov; 27(11):3131-3145. PubMed ID: 32494025
[TBL] [Abstract][Full Text] [Related]
7. USP22 regulates oncogenic signaling pathways to drive lethal cancer progression.
Schrecengost RS; Dean JL; Goodwin JF; Schiewer MJ; Urban MW; Stanek TJ; Sussman RT; Hicks JL; Birbe RC; Draganova-Tacheva RA; Visakorpi T; DeMarzo AM; McMahon SB; Knudsen KE
Cancer Res; 2014 Jan; 74(1):272-86. PubMed ID: 24197134
[TBL] [Abstract][Full Text] [Related]
8. The USP22 promotes the growth of cancer cells through the DYRK1A in pancreatic ductal adenocarcinoma.
Bai Z; Du Y; Cong L; Cheng Y
Gene; 2020 Oct; 758():144960. PubMed ID: 32687947
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-30e-5p suppresses non-small cell lung cancer tumorigenesis by regulating USP22-mediated Sirt1/JAK/STAT3 signaling.
Xu G; Cai J; Wang L; Jiang L; Huang J; Hu R; Ding F
Exp Cell Res; 2018 Jan; 362(2):268-278. PubMed ID: 29174979
[TBL] [Abstract][Full Text] [Related]
10. Knock-down of ubiquitin-specific protease 22 by micro-RNA interference inhibits colorectal cancer growth.
Xu H; Liu YL; Yang YM; Dong XS
Int J Colorectal Dis; 2012 Jan; 27(1):21-30. PubMed ID: 21773699
[TBL] [Abstract][Full Text] [Related]
11. The deubiquitinase USP22 regulates PD-L1 degradation in human cancer cells.
Wang Y; Sun Q; Mu N; Sun X; Wang Y; Fan S; Su L; Liu X
Cell Commun Signal; 2020 Jul; 18(1):112. PubMed ID: 32665011
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic USP22 supports gastric cancer growth and metastasis by activating c-Myc/NAMPT/SIRT1-dependent FOXO1 and YAP signaling.
Liu H; Liu N; Zhao Y; Zhu X; Wang C; Liu Q; Gao C; Zhao X; Li J
Aging (Albany NY); 2019 Nov; 11(21):9643-9660. PubMed ID: 31689236
[TBL] [Abstract][Full Text] [Related]
13. Ubiquitin-specific protease 7 regulates nucleotide excision repair through deubiquitinating XPC protein and preventing XPC protein from undergoing ultraviolet light-induced and VCP/p97 protein-regulated proteolysis.
He J; Zhu Q; Wani G; Sharma N; Han C; Qian J; Pentz K; Wang QE; Wani AA
J Biol Chem; 2014 Sep; 289(39):27278-27289. PubMed ID: 25118285
[TBL] [Abstract][Full Text] [Related]
14. IMP3 accelerates the progression of prostate cancer through inhibiting PTEN expression in a SMURF1-dependent way.
Zhang X; Wang D; Liu B; Jin X; Wang X; Pan J; Tu W; Shao Y
J Exp Clin Cancer Res; 2020 Sep; 39(1):190. PubMed ID: 32938489
[TBL] [Abstract][Full Text] [Related]
15. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
Zhang X; Wang Y; Ning Y
Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA‑198 suppresses prostate tumorigenesis by targeting MIB1.
Ray J; Hoey C; Huang X; Jeon J; Taeb S; Downes MR; Boutros PC; Liu SK
Oncol Rep; 2019 Sep; 42(3):1047-1056. PubMed ID: 31322262
[TBL] [Abstract][Full Text] [Related]
17. USP22 promotes development of lung adenocarcinoma through ubiquitination and immunosuppression.
Han B; Sun Y; Yang D; Zhang H; Mo S; Chen X; Lu H; Mao X; Hu J
Aging (Albany NY); 2020 Apr; 12(8):6990-7005. PubMed ID: 32294625
[TBL] [Abstract][Full Text] [Related]
18. Ubiquitin-Specific Protease 22/Silent Information Regulator 1 Axis Plays a Pivotal Role in the Prognosis and 5-Fluorouracil Resistance in Hepatocellular Carcinoma.
Wen X; Ling S; Wu W; Shan Q; Liu P; Wang C; Wei X; Ding W; Teng X; Xu X
Dig Dis Sci; 2020 Apr; 65(4):1064-1073. PubMed ID: 31587155
[TBL] [Abstract][Full Text] [Related]
19. USP22 promotes HER2-driven mammary carcinoma aggressiveness by suppressing the unfolded protein response.
Prokakis E; Dyas A; Grün R; Fritzsche S; Bedi U; Kazerouni ZB; Kosinsky RL; Johnsen SA; Wegwitz F
Oncogene; 2021 Jun; 40(23):4004-4018. PubMed ID: 34007022
[TBL] [Abstract][Full Text] [Related]
20. YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer.
Li J; Xie H; Ying Y; Chen H; Yan H; He L; Xu M; Xu X; Liang Z; Liu B; Wang X; Zheng X; Xie L
Mol Cancer; 2020 Oct; 19(1):152. PubMed ID: 33121495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
